ColoPrint is an 18-gene expression signature designed to predict disease relapse in patients with early-stage colorectal cancer (CRC). We discuss the potential impact of ColoPrint on clinical practice, and its contribution to our knowledge of CRC molecular heterogeneity.
Related Articles
Senza categoria
Newsround
Cover Story
Lynn Faulds Wood: tell it like it is
Senza categoria
Leave a Reply